Targeted therapies, however, can be very effective against established BM from different entities, such as BRAF and MEK inhibitors in melanoma, EGFR and ALK inhibitors in lung adenocarcinoma, and immune checkpoint inhibitors in melanoma and lung cancer [3, 7–10]. Here, MAP2K7 is linked to melanoma.